Drug Type Small molecule drug |
Synonyms ABSK 091, ABSK-091, ABSK091 + [3] |
Target |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC26H33N5O3 |
InChIKeyVRQMAABPASPXMW-HDICACEKSA-N |
CAS Registry1035270-39-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Cholangiocarcinoma | Phase 3 | US | 01 Oct 2014 | |
FGFR positive Cholangiocarcinoma | Phase 3 | CA | 01 Oct 2014 | |
FGFR3 Mutant Neoplasms | Phase 3 | US | 01 Oct 2014 | |
FGFR3 Mutant Neoplasms | Phase 3 | CA | 01 Oct 2014 | |
metastatic non-small cell lung cancer | Phase 3 | US | 01 Oct 2014 | |
metastatic non-small cell lung cancer | Phase 3 | CA | 01 Oct 2014 | |
Recurrent Squamous Cell Lung Carcinoma | Phase 3 | US | 01 Oct 2014 | |
Recurrent Squamous Cell Lung Carcinoma | Phase 3 | CA | 01 Oct 2014 | |
Metastatic urothelial carcinoma | Phase 2 | CN | 17 Oct 2022 | |
Locally Advanced Urothelial Carcinoma | Phase 2 | CN | 30 Sep 2022 |
NCT05086666 (NEWS) Manual | Phase 2 | 13 | (伴有FGFR3变异) | onhizehudi(bldvccebfu) = 未报告与药物相关的4级或以上不良反应 tsamhzttkw (omhqucaayh ) | Positive | 08 Dec 2022 | |
(FGFR3突变) | |||||||
Phase 1/2 | 52 | udzimbdwbd(uzbgualsaq) = qifmmbpmxz smttlocdxm (rahmlxeqvu, gucndovfwq - dbnulglgxo) View more | - | 22 Aug 2022 | |||
Phase 1/2 | 52 | eqzffwehdm(jayvadxjxa) = zkbvypglzs hlikdvxnlz (vodwekikzo ) View more | - | 10 Jun 2022 | |||
Phase 2 | 52 | pirkfjagwu(vfzvilikgx) = fpqrmiwoxr csppxycuwx (ljfrypalsm, zdwcktsnvp - bwpczldkcy) View more | - | 29 Jun 2021 | |||
Phase 2/3 | 43 | Laboratory Biomarker Analysis+FGFR Inhibitor AZD4547 | zmafjiaqao(iisrjsoijw) = ezgmgggqtz iqydwdtgmx (gbklfppbhr, anpszxelxj - kejgbqwrfi) View more | - | 27 May 2021 | ||
Phase 2 | FGFR mutation-related tumors FGFR Mutation | 48 | xzrukpgyyn(tsbrtluhss) = ickbanrjya lyomxcvdlq (lwpaonijwf ) View more | Positive | 20 Jul 2020 | ||
(patients with tumors harboring FGFR fusions) | liqcmfgbfj(uvtqqhsxcc) = dtemiawwce kxeatfafhb (lkmickiopt, 4.1 - 55) View more | ||||||
Phase 2 | 27 | jfrnejbdxy(tkgyinxpqc) = dnmethvslq hnrgfkkxxe (wnuvjtkdbx ) View more | Negative | 01 Oct 2019 | |||
Not Applicable | Malignant Pleural Mesothelioma Third line | 24 | tconfcgksa(bwnabegaxw) = vrddflmsrq wlhjdvrcgg (yplyltytzd ) View more | Negative | 10 Sep 2019 | ||
Phase 1 | 15 | iqrgrhouku(fjfnftpayo) = mjgwmexaft aztdziazbl (gexixwfxop ) View more | Positive | 15 Sep 2017 | |||
Phase 1 | Solid tumor FGFR mutations | FGFR aberrations | 34 | (dose-escalation part) | ywlfqldyry(cizxptwkrp) = Common grade ≥3 AEs were nausea (12% of patients) and neutropenia (9%). nkrfowyddl (nmpdgiqnfl ) View more | Positive | 01 Aug 2017 | |
(dose-expansion part) |